Heartseed initiated dosing in a Phase I/II trial of HS-005, an allogeneic stem cell-derived cardiomyocyte therapy for dilated cardiomyopathy delivered via catheter. Early safety data from the first patient supported trial continuation, positioning cell therapy as a potential intervention for non-ischemic heart failure.
Key Points
- HS-005 delivered via catheter to restore cardiomyocyte function in dilated cardiomyopathy
- Independent Safety Monitoring Committee cleared continuation after four-week safety review
- Trial enrolls 14 patients across dilated cardiomyopathy and ischemic heart disease cohorts
Longevity Analysis
Dilated cardiomyopathy represents progressive loss of cardiac contractile function — a foundational threat to circulation and oxygen delivery across all tissues. Cell therapy approaches that restore functional cardiomyocytes address the structural deterioration underlying heart failure rather than managing symptoms pharmacologically. Success here would establish a regenerative pathway for non-ischemic cardiomyopathy, a subset of heart failure lacking established disease-modifying therapies and responsible for significant mortality in working-age populations.
Original published by Longevity.Technology.